GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (CHIX:IDIAz) » Definitions » Total Liabilities

Idorsia (CHIX:IDIAZ) Total Liabilities : CHF1,638.95 Mil (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia Total Liabilities?

Idorsia's Total Liabilities for the quarter that ended in Sep. 2024 was CHF1,638.95 Mil.

Idorsia's quarterly Total Liabilities declined from Mar. 2024 (CHF1,717.22 Mil) to Jun. 2024 (CHF1,712.58 Mil) and declined from Jun. 2024 (CHF1,712.58 Mil) to Sep. 2024 (CHF1,638.95 Mil).

Idorsia's annual Total Liabilities increased from Dec. 2021 (CHF1,378.75 Mil) to Dec. 2022 (CHF1,565.14 Mil) but then declined from Dec. 2022 (CHF1,565.14 Mil) to Dec. 2023 (CHF1,468.71 Mil).


Idorsia Total Liabilities Historical Data

The historical data trend for Idorsia's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Total Liabilities Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 839.85 849.88 1,378.75 1,565.14 1,468.71

Idorsia Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,484.12 1,468.71 1,717.22 1,712.58 1,638.95

Idorsia Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Idorsia's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=301.326+(997.504+169.884
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1,468.71

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=499.996--968.718
=1,468.71

Idorsia's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=375.955+(1050.369+212.621
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1,638.95

Total Liabilities=Total Assets (Q: Sep. 2024 )-Total Equity (Q: Sep. 2024 )
=512.835--1126.11
=1,638.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Idorsia Total Liabilities Related Terms

Thank you for viewing the detailed overview of Idorsia's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Idorsia Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia Headlines

No Headlines